News coverage about Aduro BioTech (NASDAQ:ADRO) has been trending somewhat positive on Thursday, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aduro BioTech earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.7077965320493 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

ADRO has been the subject of a number of analyst reports. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer initiated coverage on Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price target for the company. BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.71.

Aduro BioTech (ADRO) opened at $7.60 on Thursday. The firm has a market capitalization of $591.37 and a P/E ratio of -5.59. Aduro BioTech has a 52 week low of $6.01 and a 52 week high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). The business had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.54) earnings per share. research analysts predict that Aduro BioTech will post -1.28 EPS for the current year.

In related news, EVP Dirk G. Brockstedt sold 4,123 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $8.04, for a total transaction of $33,148.92. Following the completion of the sale, the executive vice president now directly owns 77,841 shares in the company, valued at $625,841.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Stephen T. Isaacs sold 16,400 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.96, for a total value of $130,544.00. Following the sale, the chief executive officer now owns 190,321 shares of the company’s stock, valued at $1,514,955.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 316,365 shares of company stock valued at $2,858,183. Corporate insiders own 6.60% of the company’s stock.

WARNING: This article was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with's FREE daily email newsletter.